Edit
Auxilium Pharmaceuticals, Inc.
http://www.auxilium.com/Last activity: 10.09.2024
Probably Closed
Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health
Location: United States, Pennsylvania, Chesterbrook
Employees: 501-1000
Founded date: 1999
Investors 1
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
Mentions in press and media 14
| Date | Title | Description |
| 10.09.2024 | Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer | Industry veteran Daoud brings more than 25 years' experience in business development and corporate finance and strategy at multiple leading biopharmaceutical organizations WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Affinia Therapeutics ... |
| 17.01.2013 | NuPathe gets FDA approval for migraine patch | The approval for the Zecuity came more than a year after the Conshohocken, Pennsylvania-based company’s initial submission was met with a complete response letter from the U.S. Food and Drug Administration that required the company to do ad... |
| 25.07.2012 | Biopharmaceutical firm NuPathe co-founder and CEO exits, enter former Auxilium head | Incoming CEO and board member Armando Anido has 30 years of experience in the pharmaceutical industry most recently as president and CEO of Auxilium Pharmaceuticals. During his six-year tenure there he helped grow market capitalization from... |
| 04.04.2012 | Sprout Pharma takes root raising $5M for sexual dysfunction drug | Boehringer had originally studied flibanserin as a depression treatment in men and women, an endeavor that was not successful. But that depression research led to the company’s pursuit of an HSDD treatment. Similar to a depression drug, fli... |
| 23.02.2012 | Auxilium agrees to $68 million licensing deal with Swiss pharma firm | Auxilium Pharmaceuticals (NASDAQ:AUXL) has agreed to a licensing deal valued at up to $68.5 million with Swiss pharmaceutical company, Actelion. The licensing deal for its drug, Xiaflex, for the treatment of Peyronie’s disease and Dupuytren... |
| 06.02.2012 | Auxilium Pharmaceuticals shakes up management team | Auxilium Pharmaceuticals (NASDAQ: AUXL), a specialty pharmaceuticals company, has added two senior executives at the company and announced the departures of three in the latest management shakeup at the company. Andrew I. Koven has been nam... |
| 19.12.2011 | NuPathe CEO on leading a startup and the challenge of shifting fundraising dynamics | Six years after NuPathe’s launch to develop drugs for central nervous system disorders from migraines to schizophrenia to Parkinson’s disease, the company is in the process of refiling its first New Drug Application for its Zelrix migraine ... |
| - | Auxilium Pharmaceuticals shakes up management team | Auxilium Pharmaceuticals (NASDAQ: AUXL), a specialty pharmaceuticals company, has added two senior executives at the company and announced the departures of three in the latest management shakeup at the company. Andrew I. Koven has been nam... |
| - | NuPathe CEO on leading a startup and the challenge of shifting fundraising dynamics | Jane Hollingsworth, the CEO of NuPathe (NASDAQ:PATH), tends to stand out around Philadelphia. It’s not just because she has founded two drug development companies — Auxilium Pharmaceuticals (NASDAQ:AUXL) and NuPathe — and taken them public.... |
| - | NuPathe gets FDA approval for migraine patch | Migraine sufferers (and no doubt some investors) will be feeling some relief tonight after NuPathe (NASDAQ: PATH) secured approval from the U.S. Food and Drug Administration for its lead product — the first skin patch to deliver sumatriptan... |
Show more